{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:09:26Z","timestamp":1785186566550,"version":"3.55.0"},"reference-count":155,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research","award":["813716"],"award-info":[{"award-number":["813716"]}]},{"name":"European Union\u2019s Horizon 2020 research","award":["NHS2015T066"],"award-info":[{"award-number":["NHS2015T066"]}]},{"name":"European Union\u2019s Horizon 2020 research","award":["952266"],"award-info":[{"award-number":["952266"]}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation grant","doi-asserted-by":"publisher","award":["813716"],"award-info":[{"award-number":["813716"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation grant","doi-asserted-by":"publisher","award":["NHS2015T066"],"award-info":[{"award-number":["NHS2015T066"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation grant","doi-asserted-by":"publisher","award":["952266"],"award-info":[{"award-number":["952266"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project Twinning \u201cRESETageing\u201d","award":["813716"],"award-info":[{"award-number":["813716"]}]},{"name":"Project Twinning \u201cRESETageing\u201d","award":["NHS2015T066"],"award-info":[{"award-number":["NHS2015T066"]}]},{"name":"Project Twinning \u201cRESETageing\u201d","award":["952266"],"award-info":[{"award-number":["952266"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cardiovascular diseases are a major health problem, and long-term survival for people diagnosed with heart failure is, still, unrealistic. Pathological cardiac hypertrophy largely contributes to morbidity and mortality, as effective therapeutic approaches are lacking. Non-coding RNAs (ncRNAs) arise as active regulators of the signaling pathways and mechanisms that govern this pathology, and their therapeutic potential has received great attention in the last decades. Preclinical studies in large animal models have been successful in ameliorating cardiac hypertrophy, and an antisense drug for the treatment of heart failure has, already, entered clinical trials. In this review, we provide an overview of the molecular mechanisms underlying cardiac hypertrophy, the involvement of ncRNAs, and the current therapeutic landscape of oligonucleotides targeting these regulators. Strategies to improve the delivery of such therapeutics and overcome the actual challenges are, also, defined and discussed. With the fast advance in the improvement of oligonucleotide drug delivery, the inclusion of ncRNAs-targeting therapies for cardiac hypertrophy seems, increasingly, a closer reality.<\/jats:p>","DOI":"10.3390\/cells11111805","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T09:24:29Z","timestamp":1653989069000},"page":"1805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6796-7070","authenticated-orcid":false,"given":"Joana","family":"Silva","sequence":"first","affiliation":[{"name":"Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands"},{"name":"Mirabilis Therapeutics BV, 6229 EV Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"da Costa Martins","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands"},{"name":"Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.12659\/MSMBR.900437","article-title":"Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis","volume":"22","author":"Samak","year":"2016","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1006\/jmcc.1996.0134","article-title":"The role of the cytoskeleton in left ventricular pressure overload hypertrophy and failure","volume":"28","author":"Collins","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI108079","article-title":"Wall Stress and Patterns of Hypertrophy in the Human Left Ventricle","volume":"56","author":"Grossman","year":"1975","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-5273(91)90207-6","article-title":"Cardiac hypertrophy due to pressure and volume overload: Distinctly different biological phenomena?","volume":"31","author":"Rossi","year":"1991","journal-title":"Int. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/01.CIR.96.7.2239","article-title":"Pharmacological Modulation of Pressure-Overload Cardiac Hypertrophy","volume":"96","author":"Wong","year":"1997","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"H1031","DOI":"10.1152\/ajpheart.1986.251.5.H1031","article-title":"Cardiac vasculature and flow during pressure-overload hypertrophy","volume":"251","author":"Breisch","year":"1986","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/01.CIR.91.10.2504","article-title":"Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition","volume":"91","author":"Cohn","year":"1995","journal-title":"Circulation"},{"key":"ref_9","first-page":"568","article-title":"Pressure overload-induced cardiac hypertrophy varies according to different ligation needle sizes and body weights in mice","volume":"110","author":"Jia","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","article-title":"Is inhibition of hypertrophy a good therapeutic strategy in ventricular pressure overload?","volume":"131","author":"Schiattarella","year":"2015","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2011.07.022","article-title":"Left Ventricular Structural Remodeling in Health and Disease: With Special Emphasis on Volume, Mass, and Geometry","volume":"58","author":"Gaasch","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: Clinical characteristics, pathophysiology and response to treatment","volume":"22","author":"Nauta","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1172\/JCI25397","article-title":"Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction","volume":"116","author":"Perrino","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function: The Strong Heart Study","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcmg.2009.10.012","article-title":"The Impact of Obesity on the Left Ventricle. The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"3","author":"Turkbey","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-42059-2_1","article-title":"Non-coding RNAs: Classification, biology and functioning","volume":"937","author":"Hombach","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-94-017-7417-8_2","article-title":"Non-coding RNAs: An introduction","volume":"886","author":"Yang","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrg2504","article-title":"Small silencing RNAs: An expanding universe","volume":"10","author":"Ghildiyal","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-981-15-1671-9_13","article-title":"Non-coding RNAs and Pathological Cardiac Hypertrophy","volume":"1229","author":"He","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-15-1671-9_1","article-title":"An Overview of Non-coding RNAs and Cardiovascular System","volume":"1229","author":"Mushtaq","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and Mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.117.311311","article-title":"RNA therapeutics in cardiovascular disease","volume":"123","author":"Lucas","year":"2018","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating MicroRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"798954","DOI":"10.3389\/fcvm.2022.798954","article-title":"Relationship between Circulating MicroRNAs and Left Ventricular Hypertrophy in Hypertensive Patients","volume":"9","author":"Lopes","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1534\/genetics.112.146704","article-title":"Long noncoding RNAs: Past, present, and future","volume":"193","author":"Kung","year":"2013","journal-title":"Genetics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.03058","article-title":"Considerations when investigating lncRNA function in vivo","volume":"3","author":"Bassett","year":"2014","journal-title":"eLife"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cell.2011.11.055","article-title":"Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution","volume":"147","author":"Ulitsky","year":"2011","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kay, M., and Soltani, B.M. (2021). LncRNAs in Cardiomyocyte Maturation: New Window for Cardiac Regenerative Medicine. Non-Coding RNA, 7.","DOI":"10.3390\/ncrna7010020"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","article-title":"Non-coding rnas in development and disease: Background, mechanisms, and therapeutic approaches","volume":"96","author":"Beermann","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.hlc.2016.02.015","article-title":"Abundant and Altered Expression of PIWI-Interacting RNAs during Cardiac Hypertrophy","volume":"25","author":"Rajan","year":"2016","journal-title":"Heart Lung Circ."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/ijbs.26215","article-title":"Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy","volume":"14","author":"Dong","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41556-020-0576-y","article-title":"The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N 6-methyladenosine methylation of Parp10 mRNA","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4161\/rna.24285","article-title":"Small RNAs derived from the 5\u2032 end of tRNAs can inhibit protein translation in human cells","volume":"10","author":"Sobala","year":"2013","journal-title":"RNA Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shen, L., Gan, M., Tan, Z., Jiang, D., Jiang, Y., Li, M., Wang, J., Li, X., Zhang, S., and Zhu, L. (2018). A novel class of tRNA-derived small non-coding RNAs respond to myocardial hypertrophy and contribute to intergenerational inheritance. Biomolecules, 8.","DOI":"10.3390\/biom8030054"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"92079","DOI":"10.18632\/oncotarget.20759","article-title":"Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1172\/JCI33255","article-title":"The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice","volume":"118","author":"Kim","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25211-4","article-title":"A microRNA program regulates the balance between cardiomyocyte hyperplasia and hypertrophy and stimulates cardiac regeneration","volume":"12","author":"Raso","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1080\/21655979.2021.1960462","article-title":"Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating miR-145-5p\/ATF3 axis","volume":"12","author":"Pan","year":"2021","journal-title":"Bioengineered"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1161\/CIRCULATIONAHA.116.024599","article-title":"Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects against Heart Failure by Suppressing MAP2K3-p38 Signaling","volume":"135","author":"Li","year":"2017","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13596","article-title":"A long noncoding RNA protects the heart from pathological hypertrophy","volume":"514","author":"Han","year":"2014","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm.4179","article-title":"The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy","volume":"22","author":"Wang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Subrova, J., B\u00f6hme, K., Gillespie, A., Orphal, M., Plum, C., Kreutz, R., and Eisenreich, A. (2022). MiRNA-29b and miRNA-497 Modulate the Expression of Carboxypeptidase X Member 2, a Candidate Gene Associated with Left Ventricular Hypertrophy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042263"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/cvr\/cvs013","article-title":"MicroRNAs in control of cardiac hypertrophy","volume":"93","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0008-6363(00)00076-6","article-title":"Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways","volume":"47","author":"Ruwhof","year":"2000","journal-title":"Cardiovasc. Res."},{"key":"ref_48","first-page":"H552","article-title":"Differential cardiac hypertrophy and signaling pathways in pressure versus volume overload","volume":"314","author":"You","year":"2018","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/01.CIR.0000120390.68287.BB","article-title":"Hypertrophy of the Heart: A New Therapeutic Target?","volume":"109","author":"Frey","year":"2004","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1128\/MCB.01222-08","article-title":"MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes","volume":"29","author":"Ikeda","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ng1725","article-title":"The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation","volume":"38","author":"Chen","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Catalucci","year":"2007","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/HYPERTENSIONAHA.109.139519","article-title":"Reciprocal repression between MicroRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy","volume":"55","author":"Dong","year":"2010","journal-title":"Hypertension"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cvr\/cvz130","article-title":"Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy","volume":"115","author":"Lim","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-021-00552-7","article-title":"m6A modification promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2","volume":"7","author":"Qian","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/ncb2126","article-title":"MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin\/NFAT signalling","volume":"12","author":"Salic","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCULATIONAHA.106.637124","article-title":"Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling","volume":"114","author":"Ni","year":"2006","journal-title":"Circulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"C314","DOI":"10.1152\/ajpcell.00395.2013","article-title":"miR-182 attenuates atrophy-related gene expression by targeting FoxO3 in skeletal muscle","volume":"307","author":"Hudson","year":"2014","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1900023","DOI":"10.1002\/advs.201900023","article-title":"Effective Delivery of Hypertrophic miRNA Inhibitor by Cholesterol-Containing Nanocarriers for Preventing Pressure Overload Induced Cardiac Hypertrophy","volume":"6","author":"Zhi","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1074\/jbc.M111.266940","article-title":"Cardiac hypertrophy is positively regulated by microRNA miR-23a","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ncomms2090","article-title":"The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy","volume":"3","author":"Ucar","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.jacc.2021.04.028","article-title":"AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction","volume":"77","author":"Hinkel","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","first-page":"1","article-title":"Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212","volume":"9","author":"Zvara","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bao, J., Lu, Y., She, Q., Dou, W., Tang, R., Xu, X., Zhang, M., Zhu, L., Zhou, Q., and Li, H. (2021). MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease. JCI Insight, 6.","DOI":"10.1172\/jci.insight.138027"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/cvr\/cvw078","article-title":"The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy","volume":"111","author":"Liu","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"47565","DOI":"10.18632\/oncotarget.17735","article-title":"LncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII","volume":"8","author":"Shao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jss.2014.06.044","article-title":"Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo","volume":"192","author":"Yang","year":"2014","journal-title":"J. Surg. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.7150\/thno.22878","article-title":"MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress","volume":"8","author":"Yuan","year":"2018","journal-title":"Theranostics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1161\/CIRCULATIONAHA.112.000882","article-title":"MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors","volume":"127","author":"Ganesan","year":"2013","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/CIRCRESAHA.112.265736","article-title":"Direct and indirect involvement of MicroRNA-499 in clinical and experimental cardiomyopathy","volume":"111","author":"Matkovich","year":"2012","journal-title":"Circ. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1111\/jcmm.14641","article-title":"Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN\/AKT pathway","volume":"23","author":"Zhang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/ATVBAHA.111.234286","article-title":"Transforming growth factor-\u03b2-induced endothelial-to-mesenchymal transition is partly mediated by MicroRNA-21","volume":"32","author":"Kumarswamy","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.omtn.2018.05.013","article-title":"miR-217 Promotes Cardiac Hypertrophy and Dysfunction by Targeting PTEN","volume":"12","author":"Nie","year":"2018","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ymthe.2018.11.011","article-title":"Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure","volume":"27","author":"Raso","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","article-title":"Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling","volume":"8","author":"Sassi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbrc.2011.04.009","article-title":"MicroRNAs modulate the Wnt signaling pathway through targeting its inhibitors","volume":"408","author":"Liu","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, R., Salido-Medina, A.B., Gil, A., Merino, D., G\u00f3mez, J., Villar, A.V., Gonz\u00e1lez-V\u00edlchez, F., Hurl\u00e9, M.A., and Nistal, J.F. (2020). Sex-Specific Regulation of miR-29b in the Myocardium under Pressure Overload is Associated with Differential Molecular, Structural and Functional Remodeling Patterns in Mice and Patients with Aortic Stenosis. Cells, 9.","DOI":"10.3390\/cells9040833"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41467-017-00171-w","article-title":"A non-canonical pathway regulates ER stress signaling and blocks ER stress-induced apoptosis and heart failure","volume":"8","author":"Yao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/eurheartj\/ehv713","article-title":"A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223","volume":"37","author":"Wang","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCRESAHA.108.186551","article-title":"Autophagy in load-induced heart disease","volume":"103","author":"Rothermel","year":"2008","journal-title":"Circ. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1172\/JCI70877","article-title":"Enhanced autophagy ameliorates cardiac proteinopathy","volume":"123","author":"Bhuiyan","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"326ra22","DOI":"10.1126\/scitranslmed.aaf1475","article-title":"Long noncoding RNA Chast promotes cardiac remodeling","volume":"8","author":"Viereck","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/ajpheart.00711.2014","article-title":"Recent progress in research on molecular mechanisms of autophagy in the heart","volume":"308","author":"Maejima","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ymthe.2020.10.024","article-title":"Inhibition of lncRNA Gm15834 Attenuates Autophagy-Mediated Myocardial Hypertrophy via the miR-30b-3p\/ULK1 Axis in Mice","volume":"29","author":"Song","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0008-6363(97)00277-0","article-title":"Alterations of calcium-regulatory proteins in heart failure","volume":"37","author":"Hasenfuss","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","article-title":"Reversal of Cardiac Dysfunction after Long-Term Expression of SERCA2a by Gene Transfer in a Pre-Clinical Model of Heart Failure","volume":"51","author":"Kawase","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCRESAHA.118.312751","article-title":"MiR-146a Suppresses SUMO1 Expression and Induces Cardiac Dysfunction in Maladaptive Hypertrophy","volume":"123","author":"Oh","year":"2018","journal-title":"Circ. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.02.035","article-title":"MicroRNA-328 as a regulator of cardiac hypertrophy","volume":"173","author":"Li","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nature13073","article-title":"Inhibition of miR-25 improves cardiac contractility in the failing heart","volume":"508","author":"Wahlquist","year":"2014","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.7150\/thno.50990","article-title":"Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.2147\/DDDT.S245199","article-title":"Silencing of circHIPK3 Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction by Sponging miR-185-3p","volume":"14","author":"Xu","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/01.CIR.0000036760.42319.3F","article-title":"Switching metabolic genes to build a better heart","volume":"106","author":"Taegtmeyer","year":"2002","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","article-title":"Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy","volume":"96","author":"Neubauer","year":"1997","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The Failing Heart\u2014An Engine Out of Fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Li, G., Shao, Y., Guo, H.C., Zhi, Y., Qiao, B., Ma, K., Du, J., Lai, Y.Q., and Li, Y. (2021). MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling. Cardiovasc. Res., cvab248.","DOI":"10.1093\/cvr\/cvab248"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41401-020-00563-7","article-title":"MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction","volume":"42","author":"Ding","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.120.019338","article-title":"Complex Relationship between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease","volume":"10","author":"Hall","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2567.2006.02336.x","article-title":"Fibrosis in heart disease: Understanding the role of transforming growth factor-\u03b21 in cardiomyopathy, valvular disease and arrhythmia","volume":"118","author":"Khan","year":"2006","journal-title":"Immunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI70577","article-title":"Cardiac fibroblast\u2013derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy","volume":"124","author":"Bang","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.jacc.2020.02.041","article-title":"AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia\/Reperfusion Injury","volume":"75","author":"Hinkel","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e000078","DOI":"10.1161\/JAHA.113.000078","article-title":"Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling","volume":"2","author":"Karakikes","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/HYPERTENSIONAHA.117.10094","article-title":"MicroRNA-221\/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure","volume":"71","author":"Verjans","year":"2018","journal-title":"Hypertension"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: Past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.110.226936","article-title":"The emerging role of innate immunity in the heart and vascular system: For whom the cell tolls","volume":"108","author":"Mann","year":"2011","journal-title":"Circ. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_108","first-page":"169","article-title":"The possible role of peroxisome proliferator-activated receptor gamma in heart failure","volume":"9","author":"Ehara","year":"2004","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/cr.2011.132","article-title":"Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice","volume":"22","author":"Wang","year":"2012","journal-title":"Cell Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCRESAHA.114.302476","article-title":"The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489","volume":"114","author":"Wang","year":"2014","journal-title":"Circ. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","article-title":"Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation","volume":"126","author":"Mouton","year":"2020","journal-title":"Circ. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCULATIONAHA.112.001357","article-title":"Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure","volume":"128","author":"Heymans","year":"2013","journal-title":"Circulation"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1172\/JCI24682","article-title":"Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure","volume":"115","author":"Shiojima","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCULATIONAHA.110.010264","article-title":"Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure","volume":"124","author":"Banquet","year":"2011","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/mt.2012.145","article-title":"AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy","volume":"20","author":"Huusko","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yjmcc.2018.03.017","article-title":"HSF1 deficiency accelerates the transition from pressure overload-induced cardiac hypertrophy to heart failure through endothelial miR-195a-3p-mediated impairment of cardiac angiogenesis","volume":"118","author":"Wang","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1021\/ja202492e","article-title":"Nucleobase and ribose modifications control immunostimulation by a MicroRNA-122-mimetic RNA","volume":"133","author":"Peacock","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/CIRCRESAHA.116.308730","article-title":"RNA Therapeutics for Treatment of Cardiovascular Diseases: Promises and Challenges","volume":"119","author":"Lucas","year":"2016","journal-title":"Circ. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5493\/wjem.v6.i2.37","article-title":"MicroRNA-regulated viral vectors for gene therapy","volume":"6","author":"Geisler","year":"2016","journal-title":"World J. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-019-1191-6","article-title":"MicroRNA therapy stimulates uncontrolled cardiac repair after myocardialinfarction in pigs","volume":"569","author":"Gabisonia","year":"2019","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: Similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"(2020). Second RNAi drug approved. Nat. Biotechnol., 38, 385.","DOI":"10.1038\/s41587-020-0494-3"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_126","unstructured":"(2021, October 26). FDA Approves First Drug to Treat Rare Metabolic Disorder|FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-rare-metabolic-disorder."},{"key":"ref_127","unstructured":"(2021, March 21). Inclisiran Approved in Europe for Lowering LDL Cholesterol|tctmd.com. Available online: https:\/\/www.tctmd.com\/news\/inclisiran-approved-europe-lowering-ldl-cholesterol."},{"key":"ref_128","unstructured":"(2021, March 21). FDA Passes on Inclisiran, Citing Manufacturing Site Problems|tctmd.com. Available online: https:\/\/www.tctmd.com\/news\/fda-passes-inclisiran-citing-manufacturing-site-problems."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/nar\/gkl001","article-title":"In situ fluorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5","volume":"34","author":"Ohrt","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1743-422X-7-248","article-title":"Selective gene silencing by viral delivery of short hairpin RNA","volume":"7","author":"Sliva","year":"2010","journal-title":"Virol. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S162913","article-title":"Inotersen: New promise for the treatment of hereditary transthyretin amyloidosis","volume":"13","author":"Mathew","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: Results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"Hauke","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bcp.2018.11.013","article-title":"Comparison of different chemically modified inhibitors of miR-199b in vivo","volume":"159","author":"Duygu","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tox.2012.06.005","article-title":"Renal uptake and tolerability of a 2\u2019-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey","volume":"301","author":"Henry","year":"2012","journal-title":"Toxicology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/mt.2015.133","article-title":"Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?","volume":"23","author":"Philippen","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/oli.2008.0164","article-title":"Chemical modification of siRNAs for in vivo use","volume":"18","author":"Behlke","year":"2008","journal-title":"Oligonucleotides"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u201cantagomirs\u201d","volume":"438","author":"Rajewsky","year":"2005","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/nar\/gkn904","article-title":"Potent inhibition of microRNA in vivo without degradation","volume":"37","author":"Davis","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCULATIONAHA.113.001904","article-title":"Inhibition of microRNA-92a protects against ischemia\/reperfusion injury in a large-animal model","volume":"128","author":"Hinkel","year":"2013","journal-title":"Circulation"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/ard.1992.2.165","article-title":"Liposomes as a Drug Delivery System for Antisense Oligonucleotides","volume":"2","author":"Juliano","year":"1992","journal-title":"Antisense Res. Dev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/gt.2008.60","article-title":"The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transfer","volume":"15","author":"Wisse","year":"2008","journal-title":"Gene Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2014.41","article-title":"MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease","volume":"28","author":"Kordelas","year":"2014","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40259-018-0290-5","article-title":"Spherical Nucleic Acid Nanoparticles: Therapeutic Potential","volume":"32","author":"Kapadia","year":"2018","journal-title":"BioDrugs"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e000946","DOI":"10.1161\/JAHA.114.000946","article-title":"Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling","volume":"3","author":"Bellera","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","article-title":"Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies","volume":"6","author":"Morgan","year":"2021","journal-title":"JACC Basic Transl Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.114.300522","article-title":"Cardiac tissue engineering: State of the art","volume":"114","author":"Hirt","year":"2014","journal-title":"Circ. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/eurheartj\/ehz779","article-title":"Living myocardial slices: A novel multicellular model for cardiac translational research","volume":"41","author":"Perbellini","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ. Res."},{"key":"ref_155","first-page":"1","article-title":"Sex-specific regulation of cardiac microRNAs targeting mitochondrial proteins in pressure overload","volume":"10","author":"Fliegner","year":"2019","journal-title":"Biol. Sex. Differ."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/11\/1805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:22:39Z","timestamp":1760138559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/11\/1805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":155,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cells11111805"],"URL":"https:\/\/doi.org\/10.3390\/cells11111805","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}